TransMedics Group Inc Total Liabilities
TransMedics Group Inc total liabilities. Based on the latest financial reports, TransMedics Group Inc (TMDX) has total liabilities worth $946.34 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of TransMedics Group Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of TransMedics Group Inc (2006–2025)
Total liabilities of TransMedics Group Inc from 2006 to 2025. This chart illustrates how TransMedics Group Inc's total liabilities have evolved over time, based on quarterly financial data.
TransMedics Group Inc Competitors by Total Liabilities
The table below lists competitors of TransMedics Group Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Billerud AB
ST:BILL
|
Sweden | Skr20.48 Billion |
|
Ta Liang Technology Co Ltd
TW:3167
|
Taiwan | NT$7.80 Billion |
|
Civitas Resources Inc
NYSE:CIVI
|
USA | $8.43 Billion |
|
Mister Car Wash, Inc. Common Stock
NASDAQ:MCW
|
USA | $2.03 Billion |
|
Shake Shack Inc
NYSE:SHAK
|
USA | $1.36 Billion |
|
Celldex Therapeutics Inc
NASDAQ:CLDX
|
USA | $55.03 Million |
|
Vimian Group AB
ST:VIMIAN
|
Sweden | Skr401.00 Million |
|
Tongding Interconnection Information
SHE:002491
|
China | CN¥3.40 Billion |
Liability Composition Analysis (2006–2025)
This chart breaks down TransMedics Group Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see TransMedics Group Inc balance sheet assets.
Liquidity & Leverage Metrics
TransMedics Group Inc Total Liabilities Ratios Explained
TransMedics Group Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.83 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.65 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TransMedics Group Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TransMedics Group Inc (2006–2025)
The table below shows the annual total liabilities of TransMedics Group Inc from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $595.27 Million | +3.44% |
| 2024-12-31 | $575.47 Million | +1.17% |
| 2023-12-31 | $568.85 Million | +533.66% |
| 2022-12-31 | $89.77 Million | +33.91% |
| 2021-12-31 | $67.04 Million | +39.27% |
| 2020-12-31 | $48.13 Million | -4.97% |
| 2019-12-31 | $50.65 Million | +7.81% |
| 2018-12-31 | $46.98 Million | -77.16% |
| 2017-12-31 | $205.72 Million | +965.10% |
| 2016-12-31 | $19.32 Million | +216.69% |
| 2006-12-31 | $6.10 Million | -- |
About TransMedics Group Inc
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic con… Read more